Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3389-3398

  Lamoureux, François ^a   Picarda, Gaëlle ^a   Rousseau, Julie ^a   Gourden, Clothilde ^b   Battaglia, Séverine ^a   Charrier, Céline ^a   Pitard, Bruno ^a   Heymann, Dominique ^a   Rédini, Françoise ^a  

^a INSERM   (France)

^b IN CELL ART   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; COMPLEMENTARY DNA; POLOXAMER; POLYMER; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B FC; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOLYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RADIOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; ANIMAL; CELL MOTION; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; LUNG; PATHOLOGY; REPRODUCIBILITY; SOLUBILITY; SURVIVAL; TRANSGENE; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LUNG; MICE; OSTEOLYSIS; OSTEOSARCOMA; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REPRODUCIBILITY OF RESULTS; SOLUBILITY; SURVIVAL ANALYSIS; TRANSGENES; TREATMENT OUTCOME;

EID: 55749083203     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0497     Document Type: Article

References (45)

1. Klein MJ, Siegal GP. Osteosarcoma. Anatomic and histologic variants. Am J Clin Pathol 2006;125:555-81.
2. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C. The treatment of osteosarcoma of the extremities: twenty year's experience at Istituto Rizzoli. Cancer 1981;48:1569-81.
3. Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007;64:2334-50.
4. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
5. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534-40.
6. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-102.
7. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-7.
8. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
9. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: prevention of bone resorption, inhibition of tumor progression, increase of animal survival. Cancer Res 2007;67:7308-18.
10. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006;110:279-91.
11. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62: 1619-23.
12. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003;63:912-6.
13. Kapoor P, Suva LJ, Welch DR, Donahue HJ. Osteoprotegerin and the bone homing and colonization potential of breast cancer. J Cell Biochem 2008;103:30-41.
14. Yamaguchi K, Kinosaki M, Goto M, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117-23.
15. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-12.
16. Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor κB diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-90.
17. Kim D, Cho SW, Her SJ, et al. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-κB-Fc prevents bone loss in ovariectomized mice. Stem Cells 2006;24:1798-805.
18. Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther 2002;13:1767-75.
19. Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res 2004;32:e159.
20. Desigaux L, Gourden C, Bello-Roufai M, et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther 2005;16:821-9.
21. Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther 2005;16:1318-24.
22. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett 2002;188:213-9.
23. Guilloneau C, Louvet C, Renaudin K, et al. The role of TNF-related activation-induced cytokine-receptor activating NF-κB interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol 2004;172:1619-29.
24. Wittrant Y, Lamoureux F, Mori K, et al. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 2006;28:261-9.
25. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 2005;5 Suppl:S46-53.
26. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005;15:57-62.
27. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;170:49-57.
28. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005;23: 1475-83.
29. Feeley BT, Liu NO, Conduah AH, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 2006;21:1571-80.
30. Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004;86:269-79.
31. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006;29:1-9.
32. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005;23:1117-25.
33. Green LL. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999; 231:11-23.
34. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995;7:251-9.
35. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005;5:618-25.
36. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2006;61:2572-8.
37. Miller RE, Branstetter D, Armstrong A, et al. Receptor activator of NF-κB ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol 2007;179:266-74.
38. Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear factor-κB. J Pathol 2007; 211:555-62.
39. Mori K, Berreur M, Blanchard F, et al. Receptor activator of nuclear factor-κB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 2007;18: 1365-71.
40. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-6.
41. Min JK, Kim YM, Kim YM, et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-κB (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem 2003;278:39548-57.
42. Kim YM, Kim YM, Lee YM, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002;277: 6799-805.
43. + immunoregulatory T cells hinder tumor immunotherapy? J Immunother 1997;25:202-6.
44. Curotto de Lafaille MA and Lafaille JJ. CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002;14:771-8.
45. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006;12:6258-63s.